CU23204A1 - Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias - Google Patents

Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Info

Publication number
CU23204A1
CU23204A1 CU20020338A CU20020338A CU23204A1 CU 23204 A1 CU23204 A1 CU 23204A1 CU 20020338 A CU20020338 A CU 20020338A CU 20020338 A CU20020338 A CU 20020338A CU 23204 A1 CU23204 A1 CU 23204A1
Authority
CU
Cuba
Prior art keywords
hormones
growth
regulatory factors
neoplasias
combinations
Prior art date
Application number
CU20020338A
Other languages
English (en)
Inventor
Santiago Glay Chinea
Saez Yovisleidys Lopez
Dominguez Hector Hernandez
Aguilera Lesvia Calzada
More Niurka Arteaga
Aguilar Franklin Fuentes
Barranco Jesus Junco
Fuentes Eddy Bover
Nieto Gerardo Enrique Guillen
Baker Roberto Basulto
Vazquez Eulogio Pimentel
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Priority to CU20020338A priority Critical patent/CU23204A1/es
Priority to BR0317506-5A priority patent/BR0317506A/pt
Priority to PCT/CU2003/000019 priority patent/WO2004058297A1/es
Priority to CN2003801075594A priority patent/CN1732017B/zh
Priority to CA2507470A priority patent/CA2507470C/en
Priority to DE60329710T priority patent/DE60329710D1/de
Priority to MXPA05006979A priority patent/MXPA05006979A/es
Priority to RU2005123813/13A priority patent/RU2321422C2/ru
Priority to JP2004562478A priority patent/JP4384054B2/ja
Priority to AT03767380T priority patent/ATE445410T1/de
Priority to ES03767380T priority patent/ES2334344T3/es
Priority to KR1020057009823A priority patent/KR100712426B1/ko
Priority to AU2003291915A priority patent/AU2003291915B2/en
Priority to EP03767380A priority patent/EP1576965B1/en
Priority to US10/539,172 priority patent/US20060193853A1/en
Priority to MYPI20034978A priority patent/MY140305A/en
Priority to ZA200504820A priority patent/ZA200504820B/en
Publication of CU23204A1 publication Critical patent/CU23204A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001131—Epidermal growth factor [EGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001134—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]

Abstract

La presente invencion se refiere al campo de la inmunología, la endocrinología y la oncología, y en particular se basa en la generacion de respuesta inmune, de forma combinada, hacia determinados factores de crecimiento y hormonas. Un efecto sinÉrgico entre factores reguladores del crecimiento (EGF, TGF,VEGF) y de hormonas involucradas en la cascada de liberacion de hormonas sexuales, o de la reproduccion: (GnRH, LH, FSH), descubierta aquí potencia la respuesta antitumoral, expresada como reduccion de la masa tumoral y un aumento del tiempo de supervivencia.
CU20020338A 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias CU23204A1 (es)

Priority Applications (17)

Application Number Priority Date Filing Date Title
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
BR0317506-5A BR0317506A (pt) 2002-12-27 2003-12-22 Combinações farmacêuticas para o tratamento de neoplasias mediante administração simultânea, e, método para a geração de resposta imune combinada
PCT/CU2003/000019 WO2004058297A1 (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
CN2003801075594A CN1732017B (zh) 2002-12-27 2003-12-22 用于治疗瘤形成的生长调节因子和激素的组合
CA2507470A CA2507470C (en) 2002-12-27 2003-12-22 Combinations of growth regulating factors and hormones for the treatment of neoplasia
DE60329710T DE60329710D1 (de) 2002-12-27 2003-12-22 Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie
MXPA05006979A MXPA05006979A (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias.
RU2005123813/13A RU2321422C2 (ru) 2002-12-27 2003-12-22 Комбинации регулирующих рост факторов и гормонов для лечения неоплазии
JP2004562478A JP4384054B2 (ja) 2002-12-27 2003-12-22 新生物形成の処置のための増殖調節因子及びホルモンの組合せ
AT03767380T ATE445410T1 (de) 2002-12-27 2003-12-22 Kombinationen wachstums- und hormonsteuernder faktoren für die behandlung von neoplasie
ES03767380T ES2334344T3 (es) 2002-12-27 2003-12-22 Combinaciones de factores reguladores del crecimiento y de hormonas para el tratamiento de las neoplasias.
KR1020057009823A KR100712426B1 (ko) 2002-12-27 2003-12-22 종양형성의 치료를 위한 성장제어 인자 및 호르몬의 조합
AU2003291915A AU2003291915B2 (en) 2002-12-27 2003-12-22 Combinations of growth regulating factors and hormones for the treatment of neoplasia
EP03767380A EP1576965B1 (en) 2002-12-27 2003-12-22 Combinations of growth- and hormone-regulating factors for the treatment of neoplasia
US10/539,172 US20060193853A1 (en) 2002-12-27 2003-12-22 Combinations of growth-and hormone-regulating factors for the treatment of neoplasia
MYPI20034978A MY140305A (en) 2002-12-27 2003-12-24 Combination of growth regulator factors with hormones for neoplasia treatment
ZA200504820A ZA200504820B (en) 2002-12-27 2006-01-16 Combinations of growth regulaitng factors and hormones for the treatment of neoplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Publications (1)

Publication Number Publication Date
CU23204A1 true CU23204A1 (es) 2007-05-18

Family

ID=40091671

Family Applications (1)

Application Number Title Priority Date Filing Date
CU20020338A CU23204A1 (es) 2002-12-27 2002-12-27 Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias

Country Status (17)

Country Link
US (1) US20060193853A1 (es)
EP (1) EP1576965B1 (es)
JP (1) JP4384054B2 (es)
KR (1) KR100712426B1 (es)
CN (1) CN1732017B (es)
AT (1) ATE445410T1 (es)
AU (1) AU2003291915B2 (es)
BR (1) BR0317506A (es)
CA (1) CA2507470C (es)
CU (1) CU23204A1 (es)
DE (1) DE60329710D1 (es)
ES (1) ES2334344T3 (es)
MX (1) MXPA05006979A (es)
MY (1) MY140305A (es)
RU (1) RU2321422C2 (es)
WO (1) WO2004058297A1 (es)
ZA (1) ZA200504820B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8163283B2 (en) * 2009-09-03 2012-04-24 Vancouver Biotech Ltd. Monoclonal antibodies against gonadotropin-releasing hormone receptor
MX2012013702A (es) * 2010-05-26 2013-03-21 Univ Minnesota Anticuerpos anti-cd133 de fragmento variable de cadena individual y usos de los mismos.
CN104004762B (zh) * 2014-05-20 2016-03-30 南京医科大学附属南京儿童医院 Tgf-r反义序列及其在制备抗气道炎症反应药物中的应用
KR20190117541A (ko) * 2017-01-20 2019-10-16 이뮨 시스템 레귤레이션 홀딩 에이비 신규 화합물 (이뮤노렐린)
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
EP4183417A1 (en) * 2019-09-12 2023-05-24 Hexamer Therapeutics, Inc. An immunotherapeutic for prostate cancer treatment

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2228262B (en) * 1989-01-25 1992-10-07 Nat Inst Immunology Antigenic derivative of gnrh
US5211952A (en) * 1991-04-12 1993-05-18 University Of Southern California Contraceptive methods and formulations for use therein
BR9207175A (pt) * 1992-10-28 1995-12-12 Genentech Inc Composição contendo antagonista de fator de crescimento de célula endotelial vascular sequência aminoácida de anticorpo monoclonal polipeptídeo e método de tratamento de tumor em mamífero
CA2261433A1 (en) * 1993-12-09 1995-06-10 Belinda Sanchez Ramirez Composition comprising autologous epidermal growth factor
CU22627A1 (es) * 1996-12-17 2000-12-22 Ct Ingenieria Genetica Biotech Preparado vacunal para la inmuno-castración reversible de mamíferos
CU23077A1 (es) * 2000-12-06 2005-08-17 Centro Inmunologia Molecular Composicion vacunal que contiene factor de crecimiento transformante (tgf-alfa). su uso en la terapia de enfermedades malignas
US8026229B2 (en) * 2001-08-13 2011-09-27 Sterix Limited Antitumor-active 2-alkoxyestradiol sulfamates

Also Published As

Publication number Publication date
US20060193853A1 (en) 2006-08-31
CA2507470C (en) 2010-11-09
AU2003291915B2 (en) 2008-12-04
BR0317506A (pt) 2005-11-16
CA2507470A1 (en) 2004-07-15
JP2006514036A (ja) 2006-04-27
CN1732017B (zh) 2011-12-21
MXPA05006979A (es) 2005-08-16
ZA200504820B (en) 2006-03-29
JP4384054B2 (ja) 2009-12-16
DE60329710D1 (de) 2009-11-26
EP1576965B1 (en) 2009-10-14
EP1576965A1 (en) 2005-09-21
CN1732017A (zh) 2006-02-08
KR20050089016A (ko) 2005-09-07
WO2004058297A1 (es) 2004-07-15
MY140305A (en) 2009-12-31
AU2003291915A1 (en) 2004-07-22
ATE445410T1 (de) 2009-10-15
RU2321422C2 (ru) 2008-04-10
ES2334344T3 (es) 2010-03-09
RU2005123813A (ru) 2006-01-27
KR100712426B1 (ko) 2007-04-27

Similar Documents

Publication Publication Date Title
MX2019012233A (es) Anticuerpos anti-sirpa.
PH12016500871A1 (en) Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
DK1824489T3 (da) Stereoisomerisk berigede 3-arminocarbonyl-bicyclohepten-pyrimidinamin-forbindelser og anvendelse deraf
TWD164754S (zh) 可攜式無線播放器之部份
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2017011794A (es) Composiciones y metodos para diagnosticos y tratamiento del cancer.
CU23204A1 (es) Combinaciones de factores reguladores del crecimiento y hormonas para el tratamiento de neoplasias
CL2021001260A1 (es) Anticuerpos anti-sirpa humanizados
PH12020551994A1 (en) Tlr7 agonists
JOP20190241B1 (ar) مستحضرات رذاذ إبينيفرين
MX2022003184A (es) Variantes del cnp y sus conjugados.
MX2021015992A (es) Azacitidina en combinación con venetoclax, gilteritinib, midostaurina u otros compuestos para tratamiento de leucemia o síndrome mielodisplásico.
PH12021550033A1 (en) Tumor reduction formulations and methods of use thereof
WO2019043176A3 (en) HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY
MX2022006073A (es) Metodos para utilizar anticuerpos anti-trem2.
AR119271A1 (es) Administración del vector viral adenoasociado para el tratamiento de enfermedades mediadas por la calicreína plasmática desregulada
PH12021550376A1 (en) Combination therapy
MX2021005386A (es) Fragmentos de peptidos para tratamiento de diabetes.
GT200600270A (es) Uso de moduladores no esteroides de receptores de progesterona
MX2021000314A (es) Formulaciones reductoras de tumores y metodos de uso de las mismas.
MX2023005591A (es) Metodos de tratamiento de enfermedades y trastornos.
CR20220282A (es) Agonistas del tlr7
MX2020006533A (es) Inhibidores del receptor activado por proteasa-2.
MX2012007368A (es) Uso de cantaxantina y/o 25-oh d3 para mejorar el desempeño y la capacidad reproductiva de gallos.
MX2022014239A (es) Nuevos agonistas de il10 y metodos para su uso.

Legal Events

Date Code Title Description
FD Lapse (for not paying fees)